Germany's CureVac and Britain's GSK have settled a years-long patent dispute with Pfizer and its partner BioNTech over the ...

The Food and Drug Administration could pull Pfizer's coronavirus vaccine emergency authorization for children under age 5.

The chapter on Pfizer and BioNTech’s mRNA patent feud with Germany’s CureVac is coming to a close, even as lawsuits over the ...

Parents won't be able to vaccinate healthy children 6 months to 5 years old if the FDA pulls Pfizer's COVID-19 vaccine authorization.

The complicated legal wrangling has been brought to a close after CureVac and BioNTech settled their mRNA patent litigation ...

Pfizer (PFE) stock and BioNTech (BNTX) stock in focus as FDA may not renew the authorization for their pediatric COVID shot. Read more here.

American pharmaceutical giant Pfizer and German biotech firm BioNTech will pay Britain s GSK and Germany s CureVac $740 ...

CureVac (CVAC) and GSK (GSK) to receive $740M and other payments in a settlement with Pfizer (PFE) and BioNTech (BNTX) over ...

GSK and CureVac will together receive $740 million, as well as royalties on sales of COVID-19 vaccines in the US ...

The settlement ends US mRNA patent disputes involving COVID-19 and influenza vaccines, while positioning GSK for additional ...

Shortly after that, the CDC overhauled its vaccine recommendations in COVID, nixing its endorsement of the shots for pregnant women and healthy children. At the time, RFK Jr. said he “couldn’t be more ...